Drug Profile

ABS 0871

Alternative Names: ABS-0871

Latest Information Update: 21 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Actio Biosciences
Class Small molecules
Mechanism of Action TRPV4 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Charcot-Marie-Tooth disease type 2C
New Molecular Entity Yes

Highest Development Phases

Phase I Charcot-Marie-Tooth disease type 2C
Preclinical Bone disorders
Research Overactive bladder

Most Recent Events

15 Sep 2026 Actio Biosciences has been acquired by Jazz Pharmaceuticals plc
07 Feb 2025 Early research in Overactive bladder in USA (PO), (Actio Biosciences pipeline, February 2025)
07 Feb 2025 Phase-I clinical trials in Charcot-Marie-Tooth disease type-2C (In volunteers) (PO), prior to February 2025 (Actio Biosciences pipeline, February 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com